4 years ago

AffyXell Therapeutics Raises $7.3M Series A for Next-Gen Cell Therapies

  • AffyXell Therapeutics, a joint venture between Avacta Group plc and Daewoong Pharmaceutical, has secured $7.3 million in Series A funding

  • The round was led by a consortium of venture funds, including Samsung Venture Investment Corporation, Shinhan Venture Investment, Smilegate Investment, Shinhan Investment Corporation, Kolon Investment, Stonebridge Ventures, and Gyeongnam Venture Investment

  • AffyXell is developing novel mesenchymal stem cell (MSC) therapies by combining Avacta's Affimer platform with Daewoong's MSC platform

  • The funding will be used to further develop AffyXell's pipeline of next-generation cell and gene therapies, initially focusing on inflammatory and autoimmune diseases and organ transplant rejection, with potential future applications in regenerative medicine, infectious diseases, and oncology.

      • ProblemHealthcare

      "making cell and gene therapies more effective by combining Affimer proteins with mesenchymal stem cells to enhance therapeutic effects"

      Solution

      "AffyXell is genetically modifying stem cells to produce Affimer proteins in the patient, creating a next generation cell therapy platform"

      Covered on